20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Arcus Biosciences Inc (RCUS) operates in the BIOTECHNOLOGY industry and is headquartered in Hayward, United States with about 601 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, RCUS reported $247M in revenue and ($353M) in net income.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Interactive charts & full statements → Open the RCUS valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $117M | $247M | $258M | $117M | $112M | $383M | $78M | $15M | $8M | $1M | $0M |
| Gross Profit | $110M | $237M | $258M | $117M | $112M | $383M | $78M | $15M | $8M | $1M | ($1M) |
| Gross Margin % | 94.0% | 96.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Income (EBIT) | ($486M) | ($386M) | ($330M) | ($340M) | ($280M) | $54M | ($124M) | ($89M) | ($55M) | ($53M) | ($18M) |
| Operating Margin % | -415.4% | -156.3% | -127.9% | -290.6% | -250.0% | 14.1% | -159.0% | -591.4% | -656.8% | -3782.1% | — |
| Net Income | ($452M) | ($353M) | ($283M) | ($307M) | ($267M) | $53M | ($123M) | ($76M) | ($50M) | ($53M) | ($18M) |
| Net Margin % | -386.3% | -142.9% | -109.7% | -262.4% | -238.4% | 13.8% | -157.7% | -506.2% | -593.7% | -3756.7% | — |
| EBITDA | ($419M) | ($335M) | ($269M) | ($291M) | ($258M) | $59M | ($120M) | ($85M) | ($51M) | ($51M) | ($17M) |
| Earnings Per Share (EPS) | $-3.92 | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.72 | $-2.25 | $-1.73 | $-1.43 | $-2.16 | $-0.73 |
| Shares Outstanding (M) | 126M | 107M | 90M | 74M | 72M | 74M | 55M | 44M | 35M | 25M | 25M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $41M | $17M | $33M | $26M | $160M | $28M | $26M | $48M |
| Gross Profit | $41M | $15M | $30M | $24M | $160M | $28M | $26M | $48M |
| Gross Margin % | 100.0% | 88.2% | 90.9% | 92.3% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($96M) | ($134M) | ($114M) | ($142M) | ($8M) | ($122M) | ($103M) | ($105M) |
| Operating Margin % | -234.1% | -788.2% | -345.4% | -546.1% | -5.0% | -435.7% | -396.1% | -218.8% |
| Net Income | ($91M) | ($128M) | ($98M) | ($135M) | ($8M) | ($112M) | ($94M) | ($92M) |
| Net Margin % | -221.9% | -752.9% | -297.0% | -519.2% | -5.0% | -400.0% | -361.5% | -191.7% |
| EBITDA | ($85M) | ($123M) | ($81M) | ($130M) | $4M | ($108M) | ($89M) | ($89M) |
| Earnings Per Share (EPS) | $-0.72 | $-1.02 | $-0.91 | $-1.27 | $-0.08 | $-1.14 | $-1.03 | $-1.01 |
| Shares Outstanding (M) | 126M | 125M | 107M | 106M | 106M | 98M | 92M | 91M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($474M) | ($482M) | ($170M) | ($306M) | $438M | ($256M) | $111M | ($73M) | ($43M) | ($25M) | ($13M) |
| Capital Expenditures (CapEx) | $1M | $2M | $6M | $24M | $6M | $26M | $3M | $2M | $4M | $6M | $4M |
| Free Cash Flow (FCF) | ($475M) | ($484M) | ($176M) | ($330M) | $432M | ($282M) | $108M | ($75M) | ($47M) | ($31M) | ($17M) |
| FCF Margin % | -406.0% | -195.9% | -68.2% | -282.1% | 385.7% | -73.7% | 138.6% | -502.6% | -559.6% | -2163.7% | — |
| Dividends Paid | — | — | — | — | — | $5M | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($119M) | ($138M) | ($120M) | ($97M) | ($133M) | ($132M) | ($100M) | $26M |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | ($119M) | ($138M) | ($121M) | ($97M) | ($133M) | ($133M) | ($101M) | $25M |
| FCF Margin % | -290.2% | -811.8% | -366.7% | -373.1% | -83.1% | -475.0% | -388.5% | 52.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $924M | $1.1B | $1.1B | $1.1B | $1.3B | $1.6B | $772M | $203M | $275M | $190M | $110M |
| Cash & Cash Equivalents | $150M | $222M | $150M | $127M | $206M | $148M | $173M | $58M | $71M | $98M | $65M |
| Total Liabilities | $460M | $508M | $665M | $633M | $688M | $750M | $270M | $39M | $40M | $37M | $10M |
| Total Debt (Short + Long-Term) | $114M | $112M | $60M | $11M | $3M | $5M | $3M | $10M | $6M | $3M | $0M |
| Total Shareholders' Equity | $464M | $631M | $485M | $462M | $657M | $841M | $502M | $164M | $235M | $154M | $99M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RCUS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms